Traditional Chinese medicine for irritable bowel syndrome: from classic formula to modern medicine development by Zhaoxiang Bian
MEETING ABSTRACT Open Access
Traditional Chinese medicine for irritable bowel
syndrome: from classic formula to modern
medicine development
Zhaoxiang Bian
From 2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM)
Shanghai, China. 27-29 June 2012
Background
Irritable bowel syndrome (IBS) is a very common func-
tional gastrointestinal disease. Epidemiological studies
showed that 14% of males and 27% of females in the US
(white) have symptoms of IBS. In Hong Kong, one survey
reported a similar prevalence of this condition among
Chinese (3.6% in males and 3.8% in females with Rome II
criteria). Because the mechanism of IBS is not well
understood, the IBS sufferers are not satisfactory about
the symptoms management; and the new chemical drug
development targeting IBS is facing big challenges. In tra-
ditional Chinese medicine, there is no term of IBS,
although many classic literature record coving the patho-
phyioloigal concepts and therapeutic approaches bout
“painful diarrhea”.
Results
Our research group have developed a new Chinese medi-
cine formula, called JCM1602, based on “Important For-
mula for Painful Diarrhea” and our clinical therapeutic
experience. The aim of our study is to develop a modern
new drug based on the Chinese medicine theories and
modern pharmaceutical approaches. For this purpose,
firstly, we evaluated the efficacy and safety of JCM16021 in
a randomized double blinded, double dummy, control
study. Eight four patients were assigned to JCM1602 plus
placebo holopon arm, holopon plus placebo JCM1602 arm
and double placebo arm; and all patients went through
8 weeks treatment and 8 weeks follow-up. The primary
outcome is the general improvement of symptoms. Results
showed that IBS patients with JCM1602 have significant
symptom relieve during the treatment period and the
follow up period, comparing with that of the holopon
group and placebo group. Based on the clinical study
results, a new Chinese medicine drug development process
was adapted from the pharmacognosy, pharmacology, effi-
cacy, safety aspects. Further, two animal models, including
neonatal maternal separation-induced visceral hyperalgesia
model, 2,4,6-trinitrobenzene sulfonic acid-induced post
inflammatory IBS model, have been applied for the effi-
cacy confirmation and mechanism discovery.
Conclusion
The results support the efficacy of JCM1602 in patients,
and found that the analgesic effect and anti-diarrhea
effect is accomplished through serotonin pathway.
Furthermore, the active fraction of JCM1602 was identi-
fied. This active fraction is the base for the new drug
development for IBS.
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